Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-04-04
2011-12-27
Chandra, Gyan (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S866000, C514S342000, C514S365000
Reexamination Certificate
active
08084422
ABSTRACT:
The invention relates to the use of a selective inhibitor of CB2 receptor expression and/or for the manufacture of a medicament indented for the treatment and/or the prevention of obesity and obesity-related disorders.
REFERENCES:
patent: 4816397 (1989-03-01), Boss et al.
patent: 5225539 (1993-07-01), Winter
patent: 5925768 (1999-07-01), Barth et al.
patent: 5981732 (1999-11-01), Cowsert
patent: 6046321 (2000-04-01), Cowsert
patent: 6100259 (2000-08-01), Xiang et al.
patent: 6107091 (2000-08-01), Cowsert
patent: 6365354 (2002-04-01), Bennett et al.
patent: 6410323 (2002-06-01), Roberts et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 6566131 (2003-05-01), Cowsert
patent: 6566135 (2003-05-01), Watt
patent: 6573099 (2003-06-01), Graham
patent: 6916838 (2005-07-01), Barth et al.
patent: 2002/0162126 (2002-10-01), Beach et al.
patent: 2003/0027783 (2003-02-01), Zernicka-Goetz et al.
patent: 2006/0223808 (2006-10-01), Chackalamannil et al.
patent: 2006/0287322 (2006-12-01), Sun et al.
patent: 2007/0072907 (2007-03-01), Arnone et al.
Bays, Obesity Res. 12: 1197-1210, 2004.
Gertsch, Communicative and lntegr. Biol. 1: 26-28, 2008.
Kyrou Ioannis et al: “The endocannabinoid system as. a target for the treatment of visceral obesity and metabolic syndrome.” Annals of the New York Academy of Sciences Nov. 2006, vol. 1083,(Nov. 2006), pp. 270-305.
Muccioli G G et al: “Latest advalces in cannabinoid receptor antagonists and inverse agonists” Expert Opinion on Therapeutic Patents, Ashley Publications, GB, vol. 16, No. 10, 2006, pp. 1405-1423.
Pertwee R G: “The Pharmacology of Cannabinoid Receptors and Their Ligands: An Overview”, International Journal of Obesity, Newman Publishing, London, GB, vol. 30, No. Suppl 1, (Apr. 2006), pp. S13-S18.
Muccioli G et al:. “Current knowledge on the antagonists and inverse agonists of cannabinoid receptors.” Current Medicinal Chemistry 2005, vol. 12, No. 12, 2005, pp. 1361-1394.
Buckley N E et al: “Immunomodulation by Cannabinoids Is Absent in Mice Deficient for the Cannabinoid CB2 Receptor” European Journal. of Neuroscience, Oxford University Press GB, vol. 396, (May 19, 2000), pp. 141-149.
Iwamura H et al: “In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor.” The Journal of Pharmacology and Experimental Therapeutics Feb 2001, vol. 296; No. 2, pp. 420-425.
Ueda et al: “Involvement of cannabinnid CB2 receptor-mediated response and, efficacy of cannabinoid CB2 receptor inverse agonist, JTE-907, in cutaneous inflammation in mice” European Journal of Pharmacology, Amsterdam, NL, vol. 520, No. 1-3, (Sep. 27, 2005), pp. 164-171.
Raitio K H et al:. “Synthesis and SAR Studies of 2-Oxoquinoline Derivatives as CB2 Receptor Inverse Agonists” Journal of Medicinal Chemistry, American Chemical Society. Washington, US, vol. 49, No. 6, (Mar. 23, 2006), pp. 2022-2027.
Deveaux Vanessa
Lotersztajn Sophie
Mallat Ariane
Manin Sylvie
Teixeira Clerc Fatima
Chandra Gyan
Institut National de la Sante et de la Recherche Medicale (INSER
Schuman, Esq. B. Aaron
Sites & Harbison PLLC
Wright, Esq. Terry L.
LandOfFree
Method of treating insulin resistance with a selective... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating insulin resistance with a selective..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating insulin resistance with a selective... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4300213